{"url_path":"/sec/autl/8-k/2026-08-11/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1730463/0001730463-26-000119-index.html","accession_number":"0001730463-26-000119","cik":"0001730463","ticker":"AUTL","issuer_name":"Autolus Therapeutics plc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1730463/0001730463-26-000119-index.html","primary_entity_key":"0001730463","primary_entity_name":"Autolus Therapeutics plc"},"word_count":409,"has_tables":true,"body_markdown":"autl-20260811\n0001730463FALSE00017304632026-08-112026-08-110001730463sic:Z88802026-08-112026-08-110001730463us-gaap:CommonClassAMember2026-08-112026-08-11\n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWASHINGTON, D.C. 20549\n\nFORM 8-K\n\nCURRENT REPORT\n\nPursuant to Section 13 or 15(d)\n\nof the Securities Exchange Act of 1934\n\nDate of Report (Date of earliest event reported): August 11, 2026\n\nAutolus Therapeutics plc\n\n(Exact name of registrant as specified in its Charter)\n\nEngland and Wales\n001-38547\nNot applicable\n\n(State or other jurisdiction of incorporation or organization)\n(Commission File Number)\n(I.R.S. Employer Identification No.)\n\nThe Mediaworks\n\n191 Wood Lane\n\nLondonW12 7FP\n\nUnited Kingdom\n\n(Address of principal executive offices)(Zip Code)\n\n(44) 20\n3829 6230\n\n(Registrant's telephone number, including area code)\n\nNot Applicable\n\n(Former name or former address, if changed since last report)\n\nCheck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):\n\n☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\nTitle of each classTrading Symbol(s)Name of each exchange on which registered\n\nAmerican Depositary Shares, each representing one ordinary share, nominal value $0.000042 per share\nAUTLThe Nasdaq Global Select Market\n\nOrdinary shares, nominal value $0.000042 per share**\nThe Nasdaq Stock Market LLC*\n\n*\nNot for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Global Select Market. The American Depositary Shares represent the right to receive ordinary shares and are being registered under the Securities Act of 1933, as amended, pursuant to a separate Registration Statement on Form F-6. Accordingly, the American Depositary Shares are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8 thereunder.\n\nIndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\nEmerging growth company ☐\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐"}